Company Expects Growing Biosimilar Product Portfolio, Commercialized in Israel and the MENA Region, to Generate Approximately $10 Million in Annual Revenue in 2028 and Approximately $20 Million-$25 Million in Annual Revenue by 2030

REHOVOT, Israel and HOBOKEN, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced the expansion of its biosimilar portfolio with the commercial launch of two additional new products in Israel, adding to its existing portfolio of two products.

The two newly launched biosimilar products are Ustekinumab-Kamada, a biosimilar to Stelara®, a monoclonal antibody indicated for the treatment of chronic immune-mediated inflammatory diseases, including plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis, and Enoxaparin-Kamada, a biosimilar to Clexane®, a low-molecular-weight heparin indicated for the prevention and treatment of thromboembolic disorders, including deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for use in certain acute coronary syndrome settings.

The launch of the new products is in addition to the Company’s first two biosimilar products, Bevacizumab-Kamada, a biosimilar to Avastin® (Bevacizumab), and Pegfilgrastim-Kamada, a biosimilar to Neulasta®, which were launched in the Israeli market over the last two years. The Company expects the commercial availability of at least two additional biosimilar products during 2027.

All four biosimilar products were approved and launched as interchangeable with the reference original biologic product.

Kamada’s existing commercial portfolio of biosimilars is anticipated to generate approximately $4 million in sales in 2026, growing to approximately $10 million in 2028. By 2030, the Company expects this strategic portfolio to include at least 12 marketed products, licensed from 6 different leading international biosimilar companies, to be commercialized in Israel and the Middle East and North Africa (MENA) region, with the expectation to generate between approximately $20 million to $25 million in annual revenue. Kamada expects that additional biosimilar products, licensed by Kamada, will be in development or registration phase by 2030, contributing to further meaningful expansion of the portfolio.

“Kamada is building a growing and diversified biosimilars portfolio across key therapeutic areas. Our biosimilar regulatory expertise, commercialization infrastructure and market-access capabilities in Israel and the MENA region make us an attractive in-licensing partner, and we are pleased to have launched two additional biosimilars,” said Amir London, Kamada’s Chief Executive Officer. “The growth of our biosimilar product portfolio is one of our key strategic growth pillars. We continue to evaluate additional licensing opportunities that offer attractive commercial potential, and we expect this portfolio to become a meaningful contributor to our overall annual revenue growth in the years ahead.”

About Kamada
Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares. The Company’s strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth of its commercial portfolio, including continued investment in the commercialization and life cycle management of its proprietary products, consisting of six FDA-approved specialty plasma-derived products: KEDRAB®, GLASSIA®, CYTOGAM®, VARIZIG®, WINRHO SDF® and HEPAGAM B®, as well as KAMRAB®, and two equine-based anti-snake venom products. Second, distribution of third parties’ pharmaceutical products in Israel & the MENA region through in-licensing partnerships, including the launch of several biosimilar products in Israel. Third, the Company is ramping up its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing demand for hyper-immune plasma. The Company currently owns three FDA approved operating plasma collection centers in the United States, in Beaumont, Houston, and San Antonio, Texas. Fourth, the Company aims to secure new mergers and acquisitions, business development, in-licensing and/or collaboration opportunities, which are anticipated to enhance the Company’s marketed products portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term profitable growth. The Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product candidates, targeting areas of significant unmet medical need.

Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, including statements regarding: 1) the expected expansion, composition and geographic reach of Kamada’s biosimilar product portfolio; 2) the anticipated timing of the commercial availability and launch of additional biosimilar products; 3) the expected sales and annual revenue contribution of Kamada’s biosimilar product portfolio, including the anticipated generation of approximately $4 million in sales in 2026, approximately $10 million in sales in 2028 and approximately $20 million–$25 million in annual revenue by 2030; 4) the expected number of marketed biosimilar products and licensing partners by 2030; 5) the development or registration status of additional licensed biosimilar products and their potential contribution to further portfolio expansion; 6) Kamada’s ability to leverage its biosimilar regulatory expertise, commercialization infrastructure and market-access capabilities in Israel and the MENA region to remain an attractive in-licensing partner and to identify, evaluate, enter into and successfully commercialize additional in-licensing opportunities that offer attractive commercial potential; and 7) the anticipated contribution of Kamada’s biosimilar product portfolio to its future annual revenue growth, including the expectation that the portfolio will become a meaningful contributor to such growth in the years ahead. Forward-looking statements are based on Kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to the evolving nature of the conflicts in the Middle East and the impact of such conflicts in Israel, the Middle East and the rest of the world, the impact of these conflicts on market conditions and the general economic, industry and political conditions in Israel, the U.S. and globally, the effect of tariffs on overall international trade and specifically on Kamada’s ability to continue maintaining expected sales and profit levels in light of such tariffs, the effect on the establishment and timing of business initiatives, Kamada’s ability to find business development and M&A transactions and leverage such opportunities and successfully integrate such opportunities with its existing product portfolio, unexpected results of clinical and development programs, regulatory delays, and other risks detailed in Kamada’s filings with the U.S. Securities and Exchange Commission (the “SEC”) including those discussed in its most recent Annual Report on Form 20-F and in any subsequent reports on Form 6-K, each of which is on file or furnished with the SEC and available at the SEC’s website at www.sec.gov. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com

Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
britchie@LifeSciAdvisors.com

Company Expects Growing Biosimilar Product Portfolio, Commercialized in Israel and the MENA Region, to Generate Approximately $10 Million in Annual Revenue in 2028 and Approximately $20 Million-$25 Million in Annual Revenue by 2030

REHOVOT, Israel and HOBOKEN, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced the expansion of its biosimilar portfolio with the commercial launch of two additional new products in Israel, adding to its existing portfolio of two products.

The two newly launched biosimilar products are Ustekinumab-Kamada, a biosimilar to Stelara®, a monoclonal antibody indicated for the treatment of chronic immune-mediated inflammatory diseases, including plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis, and Enoxaparin-Kamada, a biosimilar to Clexane®, a low-molecular-weight heparin indicated for the prevention and treatment of thromboembolic disorders, including deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for use in certain acute coronary syndrome settings.

The launch of the new products is in addition to the Company’s first two biosimilar products, Bevacizumab-Kamada, a biosimilar to Avastin® (Bevacizumab), and Pegfilgrastim-Kamada, a biosimilar to Neulasta®, which were launched in the Israeli market over the last two years. The Company expects the commercial availability of at least two additional biosimilar products during 2027.

All four biosimilar products were approved and launched as interchangeable with the reference original biologic product.

Kamada’s existing commercial portfolio of biosimilars is anticipated to generate approximately $4 million in sales in 2026, growing to approximately $10 million in 2028. By 2030, the Company expects this strategic portfolio to include at least 12 marketed products, licensed from 6 different leading international biosimilar companies, to be commercialized in Israel and the Middle East and North Africa (MENA) region, with the expectation to generate between approximately $20 million to $25 million in annual revenue. Kamada expects that additional biosimilar products, licensed by Kamada, will be in development or registration phase by 2030, contributing to further meaningful expansion of the portfolio.

“Kamada is building a growing and diversified biosimilars portfolio across key therapeutic areas. Our biosimilar regulatory expertise, commercialization infrastructure and market-access capabilities in Israel and the MENA region make us an attractive in-licensing partner, and we are pleased to have launched two additional biosimilars,” said Amir London, Kamada’s Chief Executive Officer. “The growth of our biosimilar product portfolio is one of our key strategic growth pillars. We continue to evaluate additional licensing opportunities that offer attractive commercial potential, and we expect this portfolio to become a meaningful contributor to our overall annual revenue growth in the years ahead.”

About Kamada
Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares. The Company’s strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth of its commercial portfolio, including continued investment in the commercialization and life cycle management of its proprietary products, consisting of six FDA-approved specialty plasma-derived products: KEDRAB®, GLASSIA®, CYTOGAM®, VARIZIG®, WINRHO SDF® and HEPAGAM B®, as well as KAMRAB®, and two equine-based anti-snake venom products. Second, distribution of third parties’ pharmaceutical products in Israel & the MENA region through in-licensing partnerships, including the launch of several biosimilar products in Israel. Third, the Company is ramping up its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing demand for hyper-immune plasma. The Company currently owns three FDA approved operating plasma collection centers in the United States, in Beaumont, Houston, and San Antonio, Texas. Fourth, the Company aims to secure new mergers and acquisitions, business development, in-licensing and/or collaboration opportunities, which are anticipated to enhance the Company’s marketed products portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term profitable growth. The Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product candidates, targeting areas of significant unmet medical need.

Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, including statements regarding: 1) the expected expansion, composition and geographic reach of Kamada’s biosimilar product portfolio; 2) the anticipated timing of the commercial availability and launch of additional biosimilar products; 3) the expected sales and annual revenue contribution of Kamada’s biosimilar product portfolio, including the anticipated generation of approximately $4 million in sales in 2026, approximately $10 million in sales in 2028 and approximately $20 million–$25 million in annual revenue by 2030; 4) the expected number of marketed biosimilar products and licensing partners by 2030; 5) the development or registration status of additional licensed biosimilar products and their potential contribution to further portfolio expansion; 6) Kamada’s ability to leverage its biosimilar regulatory expertise, commercialization infrastructure and market-access capabilities in Israel and the MENA region to remain an attractive in-licensing partner and to identify, evaluate, enter into and successfully commercialize additional in-licensing opportunities that offer attractive commercial potential; and 7) the anticipated contribution of Kamada’s biosimilar product portfolio to its future annual revenue growth, including the expectation that the portfolio will become a meaningful contributor to such growth in the years ahead. Forward-looking statements are based on Kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to the evolving nature of the conflicts in the Middle East and the impact of such conflicts in Israel, the Middle East and the rest of the world, the impact of these conflicts on market conditions and the general economic, industry and political conditions in Israel, the U.S. and globally, the effect of tariffs on overall international trade and specifically on Kamada’s ability to continue maintaining expected sales and profit levels in light of such tariffs, the effect on the establishment and timing of business initiatives, Kamada’s ability to find business development and M&A transactions and leverage such opportunities and successfully integrate such opportunities with its existing product portfolio, unexpected results of clinical and development programs, regulatory delays, and other risks detailed in Kamada’s filings with the U.S. Securities and Exchange Commission (the “SEC”) including those discussed in its most recent Annual Report on Form 20-F and in any subsequent reports on Form 6-K, each of which is on file or furnished with the SEC and available at the SEC’s website at www.sec.gov. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com

Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
britchie@LifeSciAdvisors.com

DENVER, Oct. 06, 2026 (GLOBE NEWSWIRE) — The Simply Good Foods Company (NASDAQ: SMPL) (“Simply Good Foods” or the “Company”), a leader in the Nutritional Snacking category, today announced it will report financial results for the fourth quarter of Fiscal Year 2026 on Tuesday, October 27, 2026. A press release will be issued that morning, followed by a live conference call beginning at 6:30 a.m. Mountain Time (8:30 a.m. Eastern Time). Participating on the call will be Joe Scalzo, President and Chief Executive Officer and Chris Bealer, Chief Financial Officer.

Investors interested in participating in the live call can dial 877-407-0792 from the U.S., or 201-689-8263 from international locations. A live webcast, as well as a supplemental slide presentation, will be available via the “Investors” section of the Company’s website at www.thesimplygoodfoodscompany.com.

A telephone replay will be available approximately two hours after the call concludes and will remain accessible through Tuesday, November 10, 2026, by dialing 844-512-2921 from the U.S., or 412-317-6671 from international locations, and entering confirmation code 13762620.

About The Simply Good Foods Company
The Simply Good Foods Company (Nasdaq: SMPL), headquartered in Denver, Colorado, is a consumer-packaged food and beverage company with ambitious goals to raise the bar on what food can be with trusted brands and innovative nutritious snacking products. Within our portfolio of trusted brands (Quest™, Atkins™, and OWYN™), we offer a wide variety of nutritional snacks and beverages, including high protein chips, bars, ready-to-drink (RTD) shakes, and powders, and low sugar, low carb sweets and baked goods. We are a leader of the nutritious snacking movement, poised to expand our healthy lifestyle platform through innovation-driven organic growth and external investment opportunities. To learn more, visit www.thesimplygoodfoodscompany.com.

Investor Contact
Matt Siler
Vice President, Investor Relations and Treasury
The Simply Good Foods Company
msiler@simplygoodfoodsco.com

DENVER, Oct. 06, 2026 (GLOBE NEWSWIRE) — The Simply Good Foods Company (NASDAQ: SMPL) (“Simply Good Foods” or the “Company”), a leader in the Nutritional Snacking category, today announced it will report financial results for the fourth quarter of Fiscal Year 2026 on Tuesday, October 27, 2026. A press release will be issued that morning, followed by a live conference call beginning at 6:30 a.m. Mountain Time (8:30 a.m. Eastern Time). Participating on the call will be Joe Scalzo, President and Chief Executive Officer and Chris Bealer, Chief Financial Officer.

Investors interested in participating in the live call can dial 877-407-0792 from the U.S., or 201-689-8263 from international locations. A live webcast, as well as a supplemental slide presentation, will be available via the “Investors” section of the Company’s website at www.thesimplygoodfoodscompany.com.

A telephone replay will be available approximately two hours after the call concludes and will remain accessible through Tuesday, November 10, 2026, by dialing 844-512-2921 from the U.S., or 412-317-6671 from international locations, and entering confirmation code 13762620.

About The Simply Good Foods Company
The Simply Good Foods Company (Nasdaq: SMPL), headquartered in Denver, Colorado, is a consumer-packaged food and beverage company with ambitious goals to raise the bar on what food can be with trusted brands and innovative nutritious snacking products. Within our portfolio of trusted brands (Quest™, Atkins™, and OWYN™), we offer a wide variety of nutritional snacks and beverages, including high protein chips, bars, ready-to-drink (RTD) shakes, and powders, and low sugar, low carb sweets and baked goods. We are a leader of the nutritious snacking movement, poised to expand our healthy lifestyle platform through innovation-driven organic growth and external investment opportunities. To learn more, visit www.thesimplygoodfoodscompany.com.

Investor Contact
Matt Siler
Vice President, Investor Relations and Treasury
The Simply Good Foods Company
msiler@simplygoodfoodsco.com

Shareholder Support for the Merger Remains Strong with New Record Date and Shareholder Meeting to be Rescheduled

LT350 Opportunity Accelerates into National AI Infrastructure Narrative

Expanded AI Infrastructure Opportunity Since Original Record Date

BOULDER, Colo., Oct. 06, 2026 (GLOBE NEWSWIRE) — Auddia Inc. (NASDAQ: AUUD) (“Auddia” or the “Company”), an AI-first technology company pursuing a merger that, if completed, would form McCarthy Finney, an AI-native operating company, today announced the cancellation of the special shareholder meeting that was originally scheduled for September 23, 2026, but was previously adjourned to October 7, 2026. The purpose of the meeting was to vote on the Company’s proposed merger with Thramann Holdings.

Approximately 89% of votes cast on the merger were in favor of transaction, reflecting strong shareholder alignment with the Company’s strategic direction. Under Delaware law, the merger requires approval by a majority of the outstanding common shares entitled to vote at the meeting. The number of favorable votes cast was less than this required level. Our proxy solicitation advisors indicated that insufficient additional shareholders could be located from the established record date of August 3, 2026 and that this was unlikely to change.

Since the original record date, Auddia has experienced a significant expansion in strategic momentum, driven primarily by the emergence of LT350, a subsidiary of Thramann Holdings that would become a subsidiary of MCFN upon closing of the proposed merger. LT350 is developing a patented distributed datacenter platform designed to meet rapidly growing AI inference demand. LT350’s architecture deploys datacenter grade GPU infrastructure in the airspace of existing parking lots, a structural advantage that directly addresses the community resistance bottlenecks slowing datacenter expansion nationwide.

This momentum has carried over to LT350 gaining national and local attention as a common sense solution to the community resistance issues facing other data centers as evidenced by recent appearances on Fox Business News’ Varney & Co., Bloomberg News Network, Fox 17 Nashville, as well as multiple interviews with print outlets. This has accelerated the initiation of discussions with several strategic partners across fiber, real estate, enterprise, and hyperscaler ecosystems. These developments have materially increased both the clarity and magnitude of the LT350 opportunity underlying the merger.

“We are encouraged by the strong shareholder support reflected in the votes that were cast for the merger,” said Jeff Thramann, CEO of Auddia and Founder of LT350. “At the same time, the momentum surrounding LT350 has accelerated dramatically. The distributed datacenter opportunity is larger and more strategically important than previously understood, and we want shareholders to have full visibility into this growth before voting. Canceling the meeting now, as opposed to a further adjournment, allows us to align the merger vote with this expanded opportunity.”

The Company will issue a CEO Letter to Shareholders later this week providing a comprehensive update on Auddia’s progress throughout 2026, including recent developments related to LT350 and the company’s broader AI-infrastructure strategy. Following this update, and the additional announcements expected to follow, Auddia expects to establish a new record date and reschedule the shareholder meeting to vote on the proposed merger.

The Company will continue to provide updates as the process advances.

About the Merger to form McCarthy Finney (MCFN)

Auddia entered into a definitive merger agreement with Thramann Holdings, LLC on February 17, 2026. If completed, the transaction would combine Auddia with three early-stage, AI-native operating companies wholly owned by Thramann Holdings: LT350, Influence Healthcare, and Voyex. The combined company would be renamed McCarthy Finney Inc. and is expected to trade under the ticker MCFN, subject to applicable approvals and listing requirements. McCarthy Finney would operate as an AI holding company supporting LT350, Influence Healthcare, Voyex, and Auddia with AI and Web3 capabilities.

  • LT350 is a distributed AI datacenter company with 14 issued patents and 3 pending patent applications covering its proprietary solar parking lot canopy infrastructure platform. The platform integrates modular battery storage and GPU cartridges into the canopy ceiling to convert the airspace of underutilized parking areas into distributed AI datacenters. LT350 aims to build a secure, low latency, cost effective, and rapidly deployable edge network while supporting local power infrastructure resilience.
  • Influence Healthcare is a healthtech company leveraging AI, blockchain, and vertical integration to empower surgeons to drive adoption of value based care (VBC) to the surgical specialties. The Company’s mission is to leverage technology and value based enterprises (VBEs) to build an alternative healthcare system that minimizes the corporate practice of medicine, eliminates administrative waste, and enhances the autonomy and pay of health care providers to empower them to improve quality and return the patient physician relationship to the center of medicine.
  • Voyex is a travel services platform that leverages agentic AI, an integrated fintech platform, and utilization of charter and private jet aircraft to significantly improve the travel experience. The Company aims to alleviate the leading pain points for travelers of lengthy flight delays and cancellations.

About Auddia Inc.

Auddia, through its proprietary AI platform for audio identification and classification, is reinventing not only how consumers engage with AM/FM radio, podcasts, and other audio content but also how artists and labels promote their music and gain access to mainstream radio audiences. Auddia’s Discovr Radio is the first music-promotion platform to deliver artists guaranteed exposure to radio listeners. Auddia’s flagship audio superapp, called faidr, delivers multiple industry firsts, including:

  • Ad-free listening on any AM/FM radio station
  • Content skipping across any AM/FM station
  • One-touch skipping of entire podcast ad breaks
  • Integrated artist discovery experiences

For more information, visit www.auddia.com.

Cautionary Note on Forward-Looking Statements

Certain statements in this communication, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995, concerning Auddia, Thramann Holdings, and the proposed merger between Auddia and Thramann Holdings (the “Proposed Transaction”) and other matters. These forward-looking statements include, but are not limited to, express or implied statements relating to Auddia’s and Thramann Holdings’ management expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: the structure, timing and completion of the proposed merger by and between Auddia and Thramann Holdings, and the expected effects, perceived benefits or opportunities of the Proposed Transaction; the combined company’s listing on Nasdaq after the closing of the Proposed Transaction; expectations regarding the structure, timing and completion of the financing needed to close the Proposed Transaction, including investment amounts from investors, timing of closing of the Proposed Transaction, expected proceed, expectations regarding the use of proceeds, and impact on ownership structure; the anticipated timing of the closing; the expected executive officers and directors of the combined company; each company’s and the combined company’s expected cash position at the closing and cash runway of the combined company following the proposed merger and any additional financing; the future operations of the combined company, including research and development activities; the nature, strategy and focus of the combined company; the development and commercial potential and potential benefits of any products and services of the combined company; the cash balance of the combined entity at closing; expectations related to the anticipated timing of the closing of the Proposed Transaction (the “Closing”); the expectations regarding the ownership structure of the combined company; the expected trading of the combined company’s stock on Nasdaq under the ticker symbol “MCFN” after the Closing; and other statements that are not historical fact.

All statements other than statements of historical fact contained in this communication are forward-looking statements. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “opportunity,” “potential,” “milestones,” “pipeline,” “can,” “goal,” “strategy,” “target,” “anticipate,” “achieve,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “possible,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are made based on current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management, concerning future developments and their potential effects. There can be no assurance that future developments affecting Auddia, Thramann Holdings, or the Proposed Transaction will be those that have been anticipated.

These forward-looking statements involve a number of risks and uncertainties, some of which are beyond Auddia’s or Thramann Holdings’ control, or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the conditions to the Closing or consummation of the Proposed Transaction are not satisfied, including the failure to timely obtain approval of the proposed merger from Auddia’s stockholders the risk that the required financing is not obtained in a timely manner, if at all; uncertainties as to the timing of the consummation of the Proposed Transaction; risks related to Auddia’s continued listing on Nasdaq until closing of the Proposed Transaction and the combined company’s ability to remain listed following the Closing; uncertainties regarding the impact any delay in the Closing would have on the anticipated cash resources of the combined company, and other events and unanticipated spending and costs that could reduce the combined company’s cash resources; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the merger agreement; the effect of the announcement or pendency of the merger on Auddia’s or Thramann Holdings’ business relationships, operating results and business generally; costs related to the merger; the risk that as a result of adjustments to the exchange ratio, Auddia’s or Thramann Holdings’ stockholders could own more or less of the combined company than is currently anticipated; risks related to the market price of Auddia’s common stock relative to the value suggested by the exchange ratio; risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance the development of its products and services; costs of the Proposed Transaction and unexpected costs, charges or expenses resulting from the Proposed Transaction; potential adverse reactions or changes to business relationships, operating results, and business generally, resulting from the announcement or completion of the Proposed Transaction.

Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section titled “Risk Factors” in Auddia’s Annual Report on Form 10-K for the year ended December 31, 2025, which was originally filed with the SEC on March 6, 2026, subsequent Quarterly Reports on Form 10-Q filed with the SEC, and in other filings that Auddia makes and will make with the SEC in connection with the Proposed Transaction, including the Form S-4 and Proxy Statement described below, as well as discussions of potential risks, uncertainties, and other important factors included in other filings by Auddia from time to time. Should one or more of these risks or uncertainties materialize, or should any of Auddia’s or Thramann Holdings’ assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Neither Auddia nor Thramann Holdings undertakes or accepts any duty to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except as required by law. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Auddia or Thramann Holdings.

No Offer or Solicitation

This communication and the information contained herein is not intended to and does not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect of the proposed transaction or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law, or an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.

NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS COMMUNICATION IS TRUTHFUL OR COMPLETE.

Important Additional Information about the Proposed Transaction Will be Filed with the SEC

This communication relates to the proposed merger involving Auddia and Thramann Holdings and may be deemed to be solicitation material in respect of the proposed merger. In connection with the proposed Transaction, Auddia intends to file relevant materials with the SEC, including a registration statement on Form S-4 (the “Form S-4”) that will contain a proxy statement (the “Proxy Statement”) and prospectus. This communication is not a substitute for the Form S-4, the Proxy Statement or for any other document that Auddia may file with the SEC and/or send to Auddia’s stockholders in connection with the proposed merger. AUDDIA URGES, BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS TO READ THE FORM S-4, THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT AUDDIA, THRAMANN HOLDINGS, THE PROPOSED TRANSACTION AND RELATED MATTERS.

Investors and stockholders will be able to obtain free copies of the Form S-4, the Proxy Statement and other documents filed by Auddia with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. Copies of documents filed by Auddia with the SEC will also be available free of charge on Auddia’s website at www.auddia.com or by contacting Auddia Investor Relations at investors.auddiainc.com/contact. In addition, investors and stockholders should note that Auddia communicates with investors and the public through its investor-relations website at investors.auddiainc.com.

Participants in the Solicitation

Auddia, Thramann Holdings, and their respective directors and certain of their executive officers and other members of management may be deemed to be participants in the solicitation of proxies from Auddia’s stockholders in connection with the proposed transaction under the rules of the SEC. Information about Auddia’s directors and executive officers, including a description of their interests in Auddia, is included in Auddia’s most recent Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on March 6, 2026. Additional information regarding the persons who may be deemed participants in the proxy solicitations, including about the directors and executive officers of Thramann Holdings, and a description of their direct and indirect interests, by security holdings or otherwise, will also be included in the Form S-4, the Proxy Statement and other relevant materials to be filed with the SEC when they become available. These documents can be obtained free of charge from the sources indicated above.

Investor Relations:
Kirin Smith, President
PCG Advisory, Inc.
ksmith@pcgadvisory.com
www.pcgadvisory.com

Shareholder Support for the Merger Remains Strong with New Record Date and Shareholder Meeting to be Rescheduled

LT350 Opportunity Accelerates into National AI Infrastructure Narrative

Expanded AI Infrastructure Opportunity Since Original Record Date

BOULDER, Colo., Oct. 06, 2026 (GLOBE NEWSWIRE) — Auddia Inc. (NASDAQ: AUUD) (“Auddia” or the “Company”), an AI-first technology company pursuing a merger that, if completed, would form McCarthy Finney, an AI-native operating company, today announced the cancellation of the special shareholder meeting that was originally scheduled for September 23, 2026, but was previously adjourned to October 7, 2026. The purpose of the meeting was to vote on the Company’s proposed merger with Thramann Holdings.

Approximately 89% of votes cast on the merger were in favor of transaction, reflecting strong shareholder alignment with the Company’s strategic direction. Under Delaware law, the merger requires approval by a majority of the outstanding common shares entitled to vote at the meeting. The number of favorable votes cast was less than this required level. Our proxy solicitation advisors indicated that insufficient additional shareholders could be located from the established record date of August 3, 2026 and that this was unlikely to change.

Since the original record date, Auddia has experienced a significant expansion in strategic momentum, driven primarily by the emergence of LT350, a subsidiary of Thramann Holdings that would become a subsidiary of MCFN upon closing of the proposed merger. LT350 is developing a patented distributed datacenter platform designed to meet rapidly growing AI inference demand. LT350’s architecture deploys datacenter grade GPU infrastructure in the airspace of existing parking lots, a structural advantage that directly addresses the community resistance bottlenecks slowing datacenter expansion nationwide.

This momentum has carried over to LT350 gaining national and local attention as a common sense solution to the community resistance issues facing other data centers as evidenced by recent appearances on Fox Business News’ Varney & Co., Bloomberg News Network, Fox 17 Nashville, as well as multiple interviews with print outlets. This has accelerated the initiation of discussions with several strategic partners across fiber, real estate, enterprise, and hyperscaler ecosystems. These developments have materially increased both the clarity and magnitude of the LT350 opportunity underlying the merger.

“We are encouraged by the strong shareholder support reflected in the votes that were cast for the merger,” said Jeff Thramann, CEO of Auddia and Founder of LT350. “At the same time, the momentum surrounding LT350 has accelerated dramatically. The distributed datacenter opportunity is larger and more strategically important than previously understood, and we want shareholders to have full visibility into this growth before voting. Canceling the meeting now, as opposed to a further adjournment, allows us to align the merger vote with this expanded opportunity.”

The Company will issue a CEO Letter to Shareholders later this week providing a comprehensive update on Auddia’s progress throughout 2026, including recent developments related to LT350 and the company’s broader AI-infrastructure strategy. Following this update, and the additional announcements expected to follow, Auddia expects to establish a new record date and reschedule the shareholder meeting to vote on the proposed merger.

The Company will continue to provide updates as the process advances.

About the Merger to form McCarthy Finney (MCFN)

Auddia entered into a definitive merger agreement with Thramann Holdings, LLC on February 17, 2026. If completed, the transaction would combine Auddia with three early-stage, AI-native operating companies wholly owned by Thramann Holdings: LT350, Influence Healthcare, and Voyex. The combined company would be renamed McCarthy Finney Inc. and is expected to trade under the ticker MCFN, subject to applicable approvals and listing requirements. McCarthy Finney would operate as an AI holding company supporting LT350, Influence Healthcare, Voyex, and Auddia with AI and Web3 capabilities.

  • LT350 is a distributed AI datacenter company with 14 issued patents and 3 pending patent applications covering its proprietary solar parking lot canopy infrastructure platform. The platform integrates modular battery storage and GPU cartridges into the canopy ceiling to convert the airspace of underutilized parking areas into distributed AI datacenters. LT350 aims to build a secure, low latency, cost effective, and rapidly deployable edge network while supporting local power infrastructure resilience.
  • Influence Healthcare is a healthtech company leveraging AI, blockchain, and vertical integration to empower surgeons to drive adoption of value based care (VBC) to the surgical specialties. The Company’s mission is to leverage technology and value based enterprises (VBEs) to build an alternative healthcare system that minimizes the corporate practice of medicine, eliminates administrative waste, and enhances the autonomy and pay of health care providers to empower them to improve quality and return the patient physician relationship to the center of medicine.
  • Voyex is a travel services platform that leverages agentic AI, an integrated fintech platform, and utilization of charter and private jet aircraft to significantly improve the travel experience. The Company aims to alleviate the leading pain points for travelers of lengthy flight delays and cancellations.

About Auddia Inc.

Auddia, through its proprietary AI platform for audio identification and classification, is reinventing not only how consumers engage with AM/FM radio, podcasts, and other audio content but also how artists and labels promote their music and gain access to mainstream radio audiences. Auddia’s Discovr Radio is the first music-promotion platform to deliver artists guaranteed exposure to radio listeners. Auddia’s flagship audio superapp, called faidr, delivers multiple industry firsts, including:

  • Ad-free listening on any AM/FM radio station
  • Content skipping across any AM/FM station
  • One-touch skipping of entire podcast ad breaks
  • Integrated artist discovery experiences

For more information, visit www.auddia.com.

Cautionary Note on Forward-Looking Statements

Certain statements in this communication, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995, concerning Auddia, Thramann Holdings, and the proposed merger between Auddia and Thramann Holdings (the “Proposed Transaction”) and other matters. These forward-looking statements include, but are not limited to, express or implied statements relating to Auddia’s and Thramann Holdings’ management expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: the structure, timing and completion of the proposed merger by and between Auddia and Thramann Holdings, and the expected effects, perceived benefits or opportunities of the Proposed Transaction; the combined company’s listing on Nasdaq after the closing of the Proposed Transaction; expectations regarding the structure, timing and completion of the financing needed to close the Proposed Transaction, including investment amounts from investors, timing of closing of the Proposed Transaction, expected proceed, expectations regarding the use of proceeds, and impact on ownership structure; the anticipated timing of the closing; the expected executive officers and directors of the combined company; each company’s and the combined company’s expected cash position at the closing and cash runway of the combined company following the proposed merger and any additional financing; the future operations of the combined company, including research and development activities; the nature, strategy and focus of the combined company; the development and commercial potential and potential benefits of any products and services of the combined company; the cash balance of the combined entity at closing; expectations related to the anticipated timing of the closing of the Proposed Transaction (the “Closing”); the expectations regarding the ownership structure of the combined company; the expected trading of the combined company’s stock on Nasdaq under the ticker symbol “MCFN” after the Closing; and other statements that are not historical fact.

All statements other than statements of historical fact contained in this communication are forward-looking statements. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “opportunity,” “potential,” “milestones,” “pipeline,” “can,” “goal,” “strategy,” “target,” “anticipate,” “achieve,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “possible,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are made based on current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management, concerning future developments and their potential effects. There can be no assurance that future developments affecting Auddia, Thramann Holdings, or the Proposed Transaction will be those that have been anticipated.

These forward-looking statements involve a number of risks and uncertainties, some of which are beyond Auddia’s or Thramann Holdings’ control, or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the conditions to the Closing or consummation of the Proposed Transaction are not satisfied, including the failure to timely obtain approval of the proposed merger from Auddia’s stockholders the risk that the required financing is not obtained in a timely manner, if at all; uncertainties as to the timing of the consummation of the Proposed Transaction; risks related to Auddia’s continued listing on Nasdaq until closing of the Proposed Transaction and the combined company’s ability to remain listed following the Closing; uncertainties regarding the impact any delay in the Closing would have on the anticipated cash resources of the combined company, and other events and unanticipated spending and costs that could reduce the combined company’s cash resources; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the merger agreement; the effect of the announcement or pendency of the merger on Auddia’s or Thramann Holdings’ business relationships, operating results and business generally; costs related to the merger; the risk that as a result of adjustments to the exchange ratio, Auddia’s or Thramann Holdings’ stockholders could own more or less of the combined company than is currently anticipated; risks related to the market price of Auddia’s common stock relative to the value suggested by the exchange ratio; risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance the development of its products and services; costs of the Proposed Transaction and unexpected costs, charges or expenses resulting from the Proposed Transaction; potential adverse reactions or changes to business relationships, operating results, and business generally, resulting from the announcement or completion of the Proposed Transaction.

Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section titled “Risk Factors” in Auddia’s Annual Report on Form 10-K for the year ended December 31, 2025, which was originally filed with the SEC on March 6, 2026, subsequent Quarterly Reports on Form 10-Q filed with the SEC, and in other filings that Auddia makes and will make with the SEC in connection with the Proposed Transaction, including the Form S-4 and Proxy Statement described below, as well as discussions of potential risks, uncertainties, and other important factors included in other filings by Auddia from time to time. Should one or more of these risks or uncertainties materialize, or should any of Auddia’s or Thramann Holdings’ assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Neither Auddia nor Thramann Holdings undertakes or accepts any duty to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except as required by law. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Auddia or Thramann Holdings.

No Offer or Solicitation

This communication and the information contained herein is not intended to and does not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect of the proposed transaction or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law, or an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.

NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS COMMUNICATION IS TRUTHFUL OR COMPLETE.

Important Additional Information about the Proposed Transaction Will be Filed with the SEC

This communication relates to the proposed merger involving Auddia and Thramann Holdings and may be deemed to be solicitation material in respect of the proposed merger. In connection with the proposed Transaction, Auddia intends to file relevant materials with the SEC, including a registration statement on Form S-4 (the “Form S-4”) that will contain a proxy statement (the “Proxy Statement”) and prospectus. This communication is not a substitute for the Form S-4, the Proxy Statement or for any other document that Auddia may file with the SEC and/or send to Auddia’s stockholders in connection with the proposed merger. AUDDIA URGES, BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS TO READ THE FORM S-4, THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT AUDDIA, THRAMANN HOLDINGS, THE PROPOSED TRANSACTION AND RELATED MATTERS.

Investors and stockholders will be able to obtain free copies of the Form S-4, the Proxy Statement and other documents filed by Auddia with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. Copies of documents filed by Auddia with the SEC will also be available free of charge on Auddia’s website at www.auddia.com or by contacting Auddia Investor Relations at investors.auddiainc.com/contact. In addition, investors and stockholders should note that Auddia communicates with investors and the public through its investor-relations website at investors.auddiainc.com.

Participants in the Solicitation

Auddia, Thramann Holdings, and their respective directors and certain of their executive officers and other members of management may be deemed to be participants in the solicitation of proxies from Auddia’s stockholders in connection with the proposed transaction under the rules of the SEC. Information about Auddia’s directors and executive officers, including a description of their interests in Auddia, is included in Auddia’s most recent Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on March 6, 2026. Additional information regarding the persons who may be deemed participants in the proxy solicitations, including about the directors and executive officers of Thramann Holdings, and a description of their direct and indirect interests, by security holdings or otherwise, will also be included in the Form S-4, the Proxy Statement and other relevant materials to be filed with the SEC when they become available. These documents can be obtained free of charge from the sources indicated above.

Investor Relations:
Kirin Smith, President
PCG Advisory, Inc.
ksmith@pcgadvisory.com
www.pcgadvisory.com

EDMONTON, Alberta, Oct. 06, 2026 (GLOBE NEWSWIRE) — SNDL Inc. (NASDAQ: SNDL, CSE: SNDL) (“SNDL” or the “Company”) announced today that Carlo Cannell has resigned from the Board of Directors effective immediately. The Company thanks Mr. Cannell for his contributions.

ABOUT SNDL INC. 

SNDL Inc. (NASDAQ: SNDL, CSE: SNDL), through its wholly owned subsidiaries, is one of the largest vertically integrated cannabis companies and the largest private-sector liquor and cannabis retailer in Canada, with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, Spiritleaf and Cost Cannabis. With products available in licensed cannabis retail locations nationally, SNDL’s consumer-facing cannabis brands include Top Leaf, Contraband, Palmetto, Bon Jak, La Plogue, Versus, Value Buds, Grasslands, Vacay, Pearls by Grön, No Future and Bhang Chocolate. SNDL’s investment portfolio seeks to deploy strategic capital through direct and indirect investments and partnerships throughout the North American cannabis industry. For more information, please visit www.sndl.com 

For more information: 
Tomas Bottger
SNDL Inc. 
O: 1.587.327.2017 
E: investors@sndl.com

   

EDMONTON, Alberta, Oct. 06, 2026 (GLOBE NEWSWIRE) — SNDL Inc. (NASDAQ: SNDL, CSE: SNDL) (“SNDL” or the “Company”) announced today that Carlo Cannell has resigned from the Board of Directors effective immediately. The Company thanks Mr. Cannell for his contributions.

ABOUT SNDL INC. 

SNDL Inc. (NASDAQ: SNDL, CSE: SNDL), through its wholly owned subsidiaries, is one of the largest vertically integrated cannabis companies and the largest private-sector liquor and cannabis retailer in Canada, with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, Spiritleaf and Cost Cannabis. With products available in licensed cannabis retail locations nationally, SNDL’s consumer-facing cannabis brands include Top Leaf, Contraband, Palmetto, Bon Jak, La Plogue, Versus, Value Buds, Grasslands, Vacay, Pearls by Grön, No Future and Bhang Chocolate. SNDL’s investment portfolio seeks to deploy strategic capital through direct and indirect investments and partnerships throughout the North American cannabis industry. For more information, please visit www.sndl.com 

For more information: 
Tomas Bottger
SNDL Inc. 
O: 1.587.327.2017 
E: investors@sndl.com

   

VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) — Patagonia Gold Corp. (“Patagonia” or the “Company”) (TSXV: PGDC) announces corrections to the Cash Cost1 and All-In Sustaining Cost1 (“AISC”) figures, the after-tax net present value (“NPV”), internal rate of return (“IRR”), payback period, and the silver recovery assumption disclosed in its news release dated September 28, 2026 announcing the results of the independent Preliminary Economic Assessment (“PEA”) for the Calcatreu Gold-Silver Project (“Calcatreu” or the “Project”) in Río Negro Province, Argentina.

The Cash Cost and AISC figures presented in the September 28, 2026 news release inadvertently included estimated income tax. Income tax is excluded from Cash Cost and AISC under the methodology used by the Company, which is based on World Gold Council’s Guidance Note on Non-GAAP Metrics – All-In Sustaining Costs and All-In Costs. The Company also corrected the calculation of the regional development tax in the PEA model. The previous calculation inadvertently applied the respective gold and silver tax rates to total revenue, rather than applying each rate separately to the corresponding metal’s revenue.

The silver recovery assumption was incorrectly reported in the September 28, 2026 news release as 30% instead of the 45% already used in the PEA economic model. This correction relates solely to the disclosure of that assumption and does not change the modelled silver production, cost metrics or economic results.

The previously reported and revised figures for the PEA are as follows:

PEA Metric Previously Reported Revised
After-tax NPV (@10%) (US$ million) $334 $370  
After-tax IRR (%) 282%   315%
After-tax payback period (Years) 0.6   0.5  
Silver recovery (%) 30%   45%
Cash Cost1 (US$/oz Au) $2,139 $1,332  
AISC1 (US$/oz Au) $2,246 $1,439  

Figures are rounded. Cash Cost and AISC are projected life-of-mine averages, expressed per ounce of gold and net of silver by-product credits.

The exclusion of estimated income tax from Cash Cost and AISC is a presentation correction and does not affect the underlying after-tax economic analysis. The correction to the regional development tax calculation reduces the projected Cash Cost and AISC, shortens the projected after-tax payback period and increases the projected after-tax NPV and IRR through its effect on the underlying cash flows. Income tax remains included in the after-tax economic analysis.

Together, the exclusion of estimated income tax and the correction to the regional development tax calculation reduce the previously reported Cash Cost by approximately 38% and AISC by approximately 36%. The revised figures in the table above supersede the corresponding figures disclosed in the September 28, 2026 news release.

The PEA outlines an approximately 16-year mine life, a revised after-tax NPV at a 10% discount rate of approximately US$370 million, a revised after-tax IRR of approximately 315%, and a revised after-tax payback period of approximately 0.5 years, based on gold and silver prices of US$3,500/oz and US$35/oz, respectively. The mine life and metal price assumptions remain unchanged.

The economic analysis still indicates that the Project’s NPV is most sensitive to changes in the gold price and comparatively less sensitive to changes in capital costs, operating costs and the discount rate. (See Figure 1 and Table 2 below)

Figure 1: Percent change in NPV with changes in Metal Price, Capex, Opex, and Discount Rate 1

Percent change in NPV with changes in Metal Price, Capex, Opex, and Discount Rate (1)

1 Base Case (0% change) metal prices per troy ounce were US$3,500 for gold and US$35 for silver.

Table 2: Changes in NPV with changes in Metal Price, Capex, Opex and Discount Rate 2

Variation Price
(US$)
Capex
(US$ M)
Opex
(US$ M)
Discount Rate
-50 % $ 77 $ 401 $ 461 $ 464
-45 % $ 108 $ 398 $ 452 $ 453
-40 % $ 138 $ 395 $ 443 $ 442
-35 % $ 168 $ 392 $ 434 $ 432
-30 % $ 197 $ 389 $ 425 $ 422
-25 % $ 226 $ 386 $ 416 $ 413
-20 % $ 255 $ 383 $ 407 $ 404
-15 % $ 284 $ 380 $ 398 $ 395
-10 % $ 313 $ 377 $ 389 $ 386
-5 % $ 342 $ 374 $ 380 $ 378
0 %        $    370
   
5 % $ 399 $ 367 $ 361 $ 363
10 % $ 428 $ 364 $ 352 $ 356
15 % $ 457 $ 361 $ 343 $ 349
20 % $ 486 $ 358 $ 334 $ 342
25 % $ 514 $ 355 $ 325 $ 335
30 % $ 543 $ 352 $ 316 $ 329
35 % $ 572 $ 349 $ 306 $ 323
40 % $ 601 $ 346 $ 297 $ 317
45 % $ 629 $ 343 $ 287 $ 311
50 % $ 658 $ 340 $ 278 $ 306

2 Base case metal prices of US$3,500 for gold and US$35 for silver and 10% discount rate.

Christopher van Tienhoven, Chief Executive Officer of the Company, commented:

“We are providing these corrections to ensure that the cost metrics, economic results and silver recovery assumption disclosed for Calcatreu accurately reflect the PEA. The revisions exclude estimated income tax from Cash Cost and AISC and correct the regional development tax calculation, resulting in revised cost metrics, after-tax NPV, IRR and payback figures. The silver recovery correction relates solely to the previously disclosed percentage, as the economic model already used the correct assumption of 45%.”

Technical Report

The technical report being prepared in accordance with National Instrument 43-101 (“NI 43-101”), which was referenced in the September 28, 2026 news release and will be filed on the Company’s SEDAR+ profile within 45 days of such news release, will reflect the revised Cash Cost, AISC, after-tax NPV, after-tax IRR and after-tax payback period disclosed herein, together with the silver recovery assumption of 45% already incorporated in the PEA economic model.

Preliminary Economic Assessment Cautionary Statement

The PEA is preliminary in nature and includes inferred mineral resources that are considered too speculative geologically to have the economic considerations applied to them that would enable them to be categorized as mineral reserves. Mineral resources that are not mineral reserves do not have demonstrated economic viability. There is no certainty that the results of the PEA will be realized. As previously disclosed, the PEA incorporates an updated Mineral Resource Estimate (“MRE”), which contains approximately: 1.50 million tonnes of measured mineral resources grading 3.03 g/t of gold and 23.1 g/t of silver; 5.28 million tonnes of indicated mineral resources grading 2.39 g/t of gold and 23.1 g/t of silver; and 6.44 million tonnes of inferred mineral resources grading 1.54 g/t Au and 15.5 g/t Ag.

Qualified Persons

Donald J. Birak, an independent consulting geologist, Registered Member of SME and Fellow of AusIMM and Carlos Guzmán, Registered Member of the Chilean Mining Commission and Fellow of AusIMM, each a Qualified Person as defined by NI 43-101, have reviewed and approved the scientific and technical information in this news release.

For more information, please contact:

Christopher van Tienhoven
Chief Executive Officer
Patagonia Gold Corp.
T: +54 11 5278 6950
E: cvantienhoven@patagoniagold.com

FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward-looking statements include, but are not limited to, statements regarding the results and conclusions of the PEA, including the projected mine life, after-tax NPV, after-tax IRR and after-tax payback period; the sensitivity analysis and the illustrative sensitivity cases, including the effects of changes in metal prices, capital costs, operating costs and the discount rate; the underlying assumptions relating to metal prices, production, recoveries, operating and capital costs, taxes and other economic parameters; the potential development and economic performance of the Project; the anticipated timing for filing the NI 43-101 technical report and the expectation that the technical report will reflect the revised measures disclosed in this news release; the potential expansion of mineral resources through further exploration; and planned exploration, technical, permitting and development activities.

Forward-looking statements are based on management’s expectations, estimates and assumptions as at the date of this news release, including assumptions regarding the accuracy of the MRE and the geological, metallurgical, engineering, financial and economic assumptions underlying the PEA; metal prices, foreign exchange rates and metallurgical recoveries; mine plans, production schedules and processing rates; capital and operating costs; taxes, royalties and discount rates; the availability of labour, equipment, supplies, infrastructure and financing; the receipt of required permits and approvals; and the timely completion and filing of the technical report.

Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. These include the preliminary nature of the PEA and its reliance in part on inferred mineral resources; the uncertainty that the results of the PEA will be realized; uncertainties inherent in mineral resource estimates; fluctuations in commodity prices and foreign exchange rates; variations in recoveries, production, capital and operating costs; inflation and cost escalation; financing, permitting, environmental and regulatory risks; construction, development, operational and technical risks; political, legal, fiscal and social risks in Argentina; title, surface-rights and community-relations risks; exploration risks; and the other risks described in the Company’s public disclosure documents filed on SEDAR+.

Although the Company believes that the expectations and assumptions reflected in these forward-looking statements are reasonable, no assurance can be given that they will prove to be correct. Readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statement, except as required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

1 Cash Cost and AISC are non-IFRS measures. These measures have no standardized meaning under IFRS and may not be comparable to similar measures used by other issuers. The figures presented are projected life-of-mine averages derived from the PEA economic model and therefore these prospective non-IFRS financial measures may not be reconciled to the nearest comparable measure under IFRS. These measures are expressed per ounce of gold and net of silver by-product credits, excluding estimated income tax. Additional information regarding these measures and their calculation will be included in the technical report being prepared to support the PEA.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/de25ec01-b757-4830-8be1-2713ef4e21f3

VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) — Patagonia Gold Corp. (“Patagonia” or the “Company”) (TSXV: PGDC) announces corrections to the Cash Cost1 and All-In Sustaining Cost1 (“AISC”) figures, the after-tax net present value (“NPV”), internal rate of return (“IRR”), payback period, and the silver recovery assumption disclosed in its news release dated September 28, 2026 announcing the results of the independent Preliminary Economic Assessment (“PEA”) for the Calcatreu Gold-Silver Project (“Calcatreu” or the “Project”) in Río Negro Province, Argentina.

The Cash Cost and AISC figures presented in the September 28, 2026 news release inadvertently included estimated income tax. Income tax is excluded from Cash Cost and AISC under the methodology used by the Company, which is based on World Gold Council’s Guidance Note on Non-GAAP Metrics – All-In Sustaining Costs and All-In Costs. The Company also corrected the calculation of the regional development tax in the PEA model. The previous calculation inadvertently applied the respective gold and silver tax rates to total revenue, rather than applying each rate separately to the corresponding metal’s revenue.

The silver recovery assumption was incorrectly reported in the September 28, 2026 news release as 30% instead of the 45% already used in the PEA economic model. This correction relates solely to the disclosure of that assumption and does not change the modelled silver production, cost metrics or economic results.

The previously reported and revised figures for the PEA are as follows:

PEA Metric Previously Reported Revised
After-tax NPV (@10%) (US$ million) $334 $370  
After-tax IRR (%) 282%   315%
After-tax payback period (Years) 0.6   0.5  
Silver recovery (%) 30%   45%
Cash Cost1 (US$/oz Au) $2,139 $1,332  
AISC1 (US$/oz Au) $2,246 $1,439  

Figures are rounded. Cash Cost and AISC are projected life-of-mine averages, expressed per ounce of gold and net of silver by-product credits.

The exclusion of estimated income tax from Cash Cost and AISC is a presentation correction and does not affect the underlying after-tax economic analysis. The correction to the regional development tax calculation reduces the projected Cash Cost and AISC, shortens the projected after-tax payback period and increases the projected after-tax NPV and IRR through its effect on the underlying cash flows. Income tax remains included in the after-tax economic analysis.

Together, the exclusion of estimated income tax and the correction to the regional development tax calculation reduce the previously reported Cash Cost by approximately 38% and AISC by approximately 36%. The revised figures in the table above supersede the corresponding figures disclosed in the September 28, 2026 news release.

The PEA outlines an approximately 16-year mine life, a revised after-tax NPV at a 10% discount rate of approximately US$370 million, a revised after-tax IRR of approximately 315%, and a revised after-tax payback period of approximately 0.5 years, based on gold and silver prices of US$3,500/oz and US$35/oz, respectively. The mine life and metal price assumptions remain unchanged.

The economic analysis still indicates that the Project’s NPV is most sensitive to changes in the gold price and comparatively less sensitive to changes in capital costs, operating costs and the discount rate. (See Figure 1 and Table 2 below)

Figure 1: Percent change in NPV with changes in Metal Price, Capex, Opex, and Discount Rate 1

Percent change in NPV with changes in Metal Price, Capex, Opex, and Discount Rate (1)

1 Base Case (0% change) metal prices per troy ounce were US$3,500 for gold and US$35 for silver.

Table 2: Changes in NPV with changes in Metal Price, Capex, Opex and Discount Rate 2

Variation Price
(US$)
Capex
(US$ M)
Opex
(US$ M)
Discount Rate
-50 % $ 77 $ 401 $ 461 $ 464
-45 % $ 108 $ 398 $ 452 $ 453
-40 % $ 138 $ 395 $ 443 $ 442
-35 % $ 168 $ 392 $ 434 $ 432
-30 % $ 197 $ 389 $ 425 $ 422
-25 % $ 226 $ 386 $ 416 $ 413
-20 % $ 255 $ 383 $ 407 $ 404
-15 % $ 284 $ 380 $ 398 $ 395
-10 % $ 313 $ 377 $ 389 $ 386
-5 % $ 342 $ 374 $ 380 $ 378
0 %        $    370
   
5 % $ 399 $ 367 $ 361 $ 363
10 % $ 428 $ 364 $ 352 $ 356
15 % $ 457 $ 361 $ 343 $ 349
20 % $ 486 $ 358 $ 334 $ 342
25 % $ 514 $ 355 $ 325 $ 335
30 % $ 543 $ 352 $ 316 $ 329
35 % $ 572 $ 349 $ 306 $ 323
40 % $ 601 $ 346 $ 297 $ 317
45 % $ 629 $ 343 $ 287 $ 311
50 % $ 658 $ 340 $ 278 $ 306

2 Base case metal prices of US$3,500 for gold and US$35 for silver and 10% discount rate.

Christopher van Tienhoven, Chief Executive Officer of the Company, commented:

“We are providing these corrections to ensure that the cost metrics, economic results and silver recovery assumption disclosed for Calcatreu accurately reflect the PEA. The revisions exclude estimated income tax from Cash Cost and AISC and correct the regional development tax calculation, resulting in revised cost metrics, after-tax NPV, IRR and payback figures. The silver recovery correction relates solely to the previously disclosed percentage, as the economic model already used the correct assumption of 45%.”

Technical Report

The technical report being prepared in accordance with National Instrument 43-101 (“NI 43-101”), which was referenced in the September 28, 2026 news release and will be filed on the Company’s SEDAR+ profile within 45 days of such news release, will reflect the revised Cash Cost, AISC, after-tax NPV, after-tax IRR and after-tax payback period disclosed herein, together with the silver recovery assumption of 45% already incorporated in the PEA economic model.

Preliminary Economic Assessment Cautionary Statement

The PEA is preliminary in nature and includes inferred mineral resources that are considered too speculative geologically to have the economic considerations applied to them that would enable them to be categorized as mineral reserves. Mineral resources that are not mineral reserves do not have demonstrated economic viability. There is no certainty that the results of the PEA will be realized. As previously disclosed, the PEA incorporates an updated Mineral Resource Estimate (“MRE”), which contains approximately: 1.50 million tonnes of measured mineral resources grading 3.03 g/t of gold and 23.1 g/t of silver; 5.28 million tonnes of indicated mineral resources grading 2.39 g/t of gold and 23.1 g/t of silver; and 6.44 million tonnes of inferred mineral resources grading 1.54 g/t Au and 15.5 g/t Ag.

Qualified Persons

Donald J. Birak, an independent consulting geologist, Registered Member of SME and Fellow of AusIMM and Carlos Guzmán, Registered Member of the Chilean Mining Commission and Fellow of AusIMM, each a Qualified Person as defined by NI 43-101, have reviewed and approved the scientific and technical information in this news release.

For more information, please contact:

Christopher van Tienhoven
Chief Executive Officer
Patagonia Gold Corp.
T: +54 11 5278 6950
E: cvantienhoven@patagoniagold.com

FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward-looking statements include, but are not limited to, statements regarding the results and conclusions of the PEA, including the projected mine life, after-tax NPV, after-tax IRR and after-tax payback period; the sensitivity analysis and the illustrative sensitivity cases, including the effects of changes in metal prices, capital costs, operating costs and the discount rate; the underlying assumptions relating to metal prices, production, recoveries, operating and capital costs, taxes and other economic parameters; the potential development and economic performance of the Project; the anticipated timing for filing the NI 43-101 technical report and the expectation that the technical report will reflect the revised measures disclosed in this news release; the potential expansion of mineral resources through further exploration; and planned exploration, technical, permitting and development activities.

Forward-looking statements are based on management’s expectations, estimates and assumptions as at the date of this news release, including assumptions regarding the accuracy of the MRE and the geological, metallurgical, engineering, financial and economic assumptions underlying the PEA; metal prices, foreign exchange rates and metallurgical recoveries; mine plans, production schedules and processing rates; capital and operating costs; taxes, royalties and discount rates; the availability of labour, equipment, supplies, infrastructure and financing; the receipt of required permits and approvals; and the timely completion and filing of the technical report.

Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. These include the preliminary nature of the PEA and its reliance in part on inferred mineral resources; the uncertainty that the results of the PEA will be realized; uncertainties inherent in mineral resource estimates; fluctuations in commodity prices and foreign exchange rates; variations in recoveries, production, capital and operating costs; inflation and cost escalation; financing, permitting, environmental and regulatory risks; construction, development, operational and technical risks; political, legal, fiscal and social risks in Argentina; title, surface-rights and community-relations risks; exploration risks; and the other risks described in the Company’s public disclosure documents filed on SEDAR+.

Although the Company believes that the expectations and assumptions reflected in these forward-looking statements are reasonable, no assurance can be given that they will prove to be correct. Readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statement, except as required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

1 Cash Cost and AISC are non-IFRS measures. These measures have no standardized meaning under IFRS and may not be comparable to similar measures used by other issuers. The figures presented are projected life-of-mine averages derived from the PEA economic model and therefore these prospective non-IFRS financial measures may not be reconciled to the nearest comparable measure under IFRS. These measures are expressed per ounce of gold and net of silver by-product credits, excluding estimated income tax. Additional information regarding these measures and their calculation will be included in the technical report being prepared to support the PEA.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/de25ec01-b757-4830-8be1-2713ef4e21f3

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.